| Business Summary | | BioSource
International,
Inc.
develops,
manufactures,
markets
and
distributes
products
used
worldwide
in
biomedical
research
that
are
instrumental
in
the
development
of
new
drug
therapies
and
medical
diagnostic
methods.
The
Company's
products
enable
scientists
and
biomedical
researchers
to
better
understand
the
biochemistry,
immunology
and
cell
biology
of
the
human
body,
as
well
as
disease
processes.
The
Company
offers
over
3,200
products
that
it
groups
into
Assays;
Antibodies;
Bioactive
Proteins
and
Peptides;
Oligonucleotides,
and
Serum,
Buffers
and
Media
product
lines. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Biosource
International
develops,
manufactures,
markets
and
distributes
products
used
in
disease
related
biomedical
research
and
clinical
diagnostics,
principally
in
the
fields
of
immunology
and
molecular
biology.
For
the
six
months
ended
6/30/01,
net
sales
rose
7%
to
$17.4
million.
Net
income
applicable
to
Common
totaled
$524
thousand,
up
from
$20
thousand.
Results
reflect
increased
sales
in
North
America,
and
the
absence
of
$1.5
million
in
preferred
dividends
and
accretion. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Jean-Pierre Conte, 37 Interim
Chairman | -- | -- | James Chamberlain, 53 Interim
CEO | $350K | $1.7M | Charles Best, 41 Exec.
VP of Fin., CFO | 165K | 81K | David Thrower, 37 Sr.
VP, Global Marketing | -- | -- | Cirilo Cabradilla, Ph.D., 53 VP,
Molecular Biology | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|